SciClone says treatment with Zadaxin doubles skin cancer response rate

By Angela McDaniels

Seattle, Sept. 18 - SciClone Pharmaceuticals, Inc. and Sigma-Tau SpA said interim data shows that the addition of Zadaxin to standard dacarbazine chemotherapy, with or without interferon alpha, in patients with the most advanced form of metastatic malignant melanoma achieved double the overall tumor response compared with the control group.

Of the 99 patients treated with 3.2 mg of Zadaxin in combination with dacarbazine, 12.1% achieved an overall response (complete and partial response) which was more than double the 5.3% response for the 95 patients in the control arm.

Interim results from the ongoing phase 2 clinical trial were presented on Saturday at the joint Perspectives in Melanoma X and the Third International Melanoma Research Congress in Noordwijk, the Netherlands. The data included 463 of the 485 patients in this five-arm clinical trial.

SciClone is a San Mateo, Calif., biopharmaceutical company. Sigma-Tau is SciClone's European development and marketing partner.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.